Immutep to discontinue TACTI-004 Phase III study in first line NSCLC
#Immutep #TACTI-004 #Phase III #NSCLC #clinical trial discontinuation #first-line treatment #non-small cell lung cancer
📌 Key Takeaways
- Immutep is discontinuing its TACTI-004 Phase III clinical trial.
- The study focused on first-line treatment for non-small cell lung cancer (NSCLC).
- The decision follows a planned interim analysis of the trial's data.
- The discontinuation suggests the trial did not meet its efficacy or safety endpoints.
🏷️ Themes
Clinical Trial, Oncology
📚 Related People & Topics
Immutep
Biotechnology company
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep...
Non-small-cell lung cancer
Any type of epithelial lung cancer other than small-cell lung carcinoma
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is a type of epithelial lung cancer other than small-cell lung cancer (SCLC). Non-small-cell lung cancer accounts for about 85% of all lung cancers. As a class, non-small-cell lung cancers are relatively insensitive to chemotherap...
Entity Intersection Graph
Connections for Immutep:
Mentioned Entities
Deep Analysis
Why It Matters
This news is important because it represents a significant setback in cancer treatment development, particularly for non-small cell lung cancer (NSCLC) patients who have limited first-line treatment options. The discontinuation affects cancer patients hoping for new therapies, investors in Immutep and the biotech sector, and the broader oncology research community. It highlights the high failure rate of late-stage clinical trials in oncology and may impact future investment in similar immunotherapy approaches.
Context & Background
- Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer deaths worldwide.
- TACTI-004 was evaluating eftilagimod alpha (efti), an LAG-3 agonist, in combination with pembrolizumab (Keytruda) as first-line treatment for metastatic NSCLC patients with PD-L1 positive tumors.
- Phase III trials represent the final stage of clinical testing before potential regulatory approval, making discontinuation at this stage particularly significant and costly.
- LAG-3 is an emerging immune checkpoint target, with Bristol Myers Squibb's relatlimab (combined with nivolumab) being the first FDA-approved LAG-3 inhibitor in 2022 for melanoma.
What Happens Next
Immutep will conduct a full analysis of the TACTI-004 data to understand why the trial failed to meet its endpoints, with results likely to be presented at medical conferences or published in journals. The company will shift resources to its other clinical programs, particularly TACTI-003 in head and neck cancer and INSIGHT-003 in various solid tumors. Investors will watch for Immutep's next earnings call for detailed explanations and revised corporate strategy, while regulatory agencies may review the data for insights into LAG-3 targeting approaches.
Frequently Asked Questions
TACTI-004 was a Phase III clinical trial testing eftilagimod alpha combined with pembrolizumab as first-line treatment for metastatic non-small cell lung cancer patients with PD-L1 positive tumors. The trial aimed to improve outcomes compared to pembrolizumab alone, which is a current standard treatment for this patient population.
While the specific reasons haven't been fully disclosed, Phase III trials are typically discontinued when interim analyses show the treatment is unlikely to demonstrate statistically significant improvement over existing therapies. This could be due to insufficient efficacy, safety concerns, or failure to meet predefined endpoints.
This discontinuation means NSCLC patients won't have access to this particular combination therapy in the near future. However, patients currently enrolled in the trial will continue to be monitored, and the data collected may inform future research directions for LAG-3 targeting in lung cancer.
Immutep will face significant financial implications including sunk R&D costs, potential stock price decline, and possible restructuring. However, the company can redirect resources to other promising programs, potentially mitigating long-term damage if other trials succeed.
Yes, several other LAG-3 targeting therapies remain in development across various companies. Bristol Myers Squibb's relatlimab is already approved for melanoma, and other biopharmaceutical companies continue investigating LAG-3 inhibitors for various cancers, suggesting the target remains scientifically valid despite this setback.